chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I received the vaccine at near noon on 01/08/2007 on the L deltoid.  I experienced injection site pain and swelling initially.  Over the next few hours, the pain spread to the L side of my neck and then to my L elbow.  At 9:45 pm, I developed paresthesia in my L hand.  Within minutes, I felt paresthesias in my L foot, L lower leg, L side of my face, both lips, R hand, R foot, and R lower leg.  I felt pre-syncopal soon after.  At 10 pm, I was driven to the ER.  During the 20 minute car ride, the rigors began.  The rigors resolved after 90 minutes.  On the next day, 01/09/2007, I had fatigue, myalgias, and diarrhea and I was unable to work.  Those symptoms resolved by the next day, but all the paresthesias persisted.  On 01/10/2007, I was evaluated by a neurologist.  Today on 01/12/2007, I still have paresthesias.
Wednesday morning I was woke up really light headed with chest discomfort. Wednesday night I was still light headed and experiencing discomfort so I called my doctor Thursday morning and I went to the ER and got a chest x ray, ultra sound and blood work done. All tests came back normal and about a few days later I was back to doing my normal daily activities.
Shingles; This is a spontaneous report from a contactable consumer (the patient) from a Pfizer-sponsored program COVAX US Support. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient has an appointment for the second dose on Friday (unspecified date) but ended up in the Emergency room due to shingles. She's on antiviral and wanted to know if she will continue getting the second dose. The outcome of the event was unknown.   Information on the lot/batch number has been requested.
Information has been received from a 49-year-old female with an allergy to "arrythnomyacin" and a history of "toxic build up of mercury", who on 28-DEC-2005 was vaccinated with a dose of Recombivax HB. Concomitant vaccination given on that same day included: a booster dose of Vaqta (lot# 649456/0175R). On 29-DEC-2005, the patient experienced black tongue. It was reported that the patient was post menopausal, however, developed vaginal bleeding "four days ago" (08-JAN-2006). Unspecified medical attention was sought. No laboratory or diagnostic tests were performed. At the time of this report the patient had not recovered. No product quality complaint was involved.  Additional information has been requested.
Pain during injection process from site of fingers. Pain rated 8 on 1-10 scale for remainder of day and into day 3. Since the injection, pain is from upper arm to fingers. It is a continuous dull ache, with severe pain upon use. Unable to sleep on left side. Appt. with PCP on Oct 20, 2014 and was treated with ice and ibuprofen and has a follow up appt. 11/7/14. Left hand coldness.
nume on arm, fever, chills, tiredness, num on tongue, diarrhea, stomach ache, headache, nausea,
Patient was instructed by her allergist to receive her 2nd dose (0.5 ml) of Moderna Covid-19 vaccine. Approximately 5-10 minutes after receiving her 2nd dose, patient commented that her throat felt a little tight. She declined to have emergency services called on her behalf. Patient commented that after her 1st dose she had a similar incident that was treated by her primary care, anaphylaxis ruled out. Patient was declined by her employer for an exemption for vaccine mandate because her 1st dose was not an anaphylactic reaction. RPh again offered to call EMS, patient (accompanied by a friend) said she would just go to the emergency room herself.
Client received 1st dose of Pfizer (lot #EW0177) with on 6/11/21. She provided vaccination card with proof and was cleared. Client did not have any reaction to her first dose. Requested to get 2nd dose and our team only had Moderna and JJ which we informed her that it is recommended to receive another mRNA vaccine. Client agreed to get Moderna as second dose and was monitored for 15 min with no reactions.
Case number PHEH2014US012911 is an initial spontaneous report received from the medical assistant on 25 Jun 2014 with a follow up information received from a medical assistant on 29 Jul 2014. This report refers to a 12 years old female patient. Her medical history and concomitant medications were not reported. She was vaccinated with a dose of MENVEO (batch number: A13058) intramuscularly in the left arm on 25 Jun 2014 at 1:50 pm. It was reported that she received 0.5 ml MenA lyophilized conjugate of MENVEO was reconstituted with sterile water instead of the Men CYW-135 liquid conjugate. No adverse event reported after the maladministration.Follow up information received from a medical assistant on 29 Jul 2014: Patient demographics (height and weight) and site of vaccination updated.
1st day after vaccine. Chills, fever, fatigue, headache, 2nd day- stiff neck, headache. 3rd day after vaccine - left side of face sore, headache, earache. 4thday -Chest pains,- very quick, sharp, very tired, had heart skip/ palpations went to ER @ 11:30pm.  Had EKG, blood work, stress test from cardio dept. Followed up with Dr.  with cardio dept. received Zio patch Heart Monitor and wore for 2 weeks. Currently waiting the results.
Site: Pain at Injection Site-Medium, Systemic: Numbness (specify: facial area, extremities)-Medium, Systemic: Tingling (specify: facial area, extemities)-Medium, Additional Details: She had pain in neck area and tingling down her arm within about 10 minutes of receiving the shot. An hour later she thought pain in neck had intensified and md suggested tylenol and ice. 24 hours later, she says tingling is gone and just mild soreness in neck area.
shortness of breath; fatique; loss of taste and smell; loss of taste and smell; received the "flu vaccine" 3 days before contracting COVID; This case was reported by a consumer via other manufacturer and described the occurrence of covid-19 in a 47-year-old patient who received Flu Seasonal QIV Dresden (Influenza vaccine Quadrivalent 2020-2021 season) for prophylaxis.   The patient's past medical history included post concussion syndrome, irritable bowel syndrome (gastro symptoms were similar but differrent than IBS in 2017), covid-19 (Family History) (1stly patient's brother got infected and then father got infected on 7th October 2020 and then whole family) and diabetes (Family History) (father was diabetic). Concurrent medical conditions included hormonal imbalance (had low progesterone and was taking supplemental progesterone monthly) and drug allergy. Concomitant products included pregabalin (Lyrica), progesterone and ibuprofen.   On 28th October 2020, the patient received Influenza vaccine Quadrivalent 2020-2021 season. On 31st October 2020, 3 days after receiving Influenza vaccine Quadrivalent 2020-2021 season, the patient experienced covid-19. On an unknown date, the patient experienced shortness of breath, fatigue, taste loss and loss of smell. On an unknown date, the outcome of the covid-19, shortness of breath, fatigue, taste loss and loss of smell were unknown.   It was unknown if the reporter considered the covid-19, shortness of breath, fatigue, taste loss and loss of smell to be related to Influenza vaccine Quadrivalent 2020-2021 season.  Additional details were provided are as follows: The patient received flu vaccine 3 days prior to contracting COVID-19 On 17th October 2020,14th October 2020 and 21st October 2020, the patient was tested Covid negative but on 31st October 2020, the patient's Covid test was positive for the 1st time. On 5th February 2021, the patient received 1st dose of Covid vaccine from pfizer along with some Pharma products and experienced some adverse events, for tolerance refer linked case US2021AMR147346 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR147346:Same reporter
After vaccination the patient started voicing that they were seeing black dots, feeling lightheaded.  Patient laid down for 10 minutes, consumed glucose and drank water. Patient voiced that they were feeling better soon after.
miscarried at 12 weeks; received first dose of bnt162b2 on 18Dec2020, second dose on 11Feb2021; received first dose of bnt162b2 on 18Dec2020, second dose on 11Feb2021; This is a spontaneous report from a contactable nurse (Patient). A 38-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number el3248) intramuscular in right arm on 11Feb2021 17:00 at single dose for covid-19 immunisation. No medical history. No COVID prior to vaccination. Other medications in two weeks include prenatal vitamins. Patient received first dose of bnt162b2 (lot number ek5730) on 18Dec2020 12:00 PM intramuscular in right arm. No other vaccine in four weeks. Patient's last menstrual date was 01Nov2020. Patient miscarried at 12 weeks after receiving the second dose of vaccine. Dilation and curettage performed. Outcome was recovered with sequel. Nasal Swab COVID tested negative post vaccination on 18Feb2021.; Sender's Comments: The limited information provided precludes a full clinical assessment of the case. Considering the product-event temporal relationship, a causal association between the reported 'miscarried' and the administration of bnt162b2 cannot be completely excluded. Case will be reassessed once with additional information.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Upon interview, patient denies history of varicella illness and could not recall vaccination prior to in processing. Multiple, different size maculo-vesicular rash over the face, chest, abdomen, upper and lower extremities skin. Patient has been afebrile and pain free. Patient was serologically tested and found varicella non-immune upon entry (7/2/2008). Patient received varicella vaccination on 7/9/2008. Patient received second dose of varicella vaccination on 8/8/2008. While admitted to hospital, diagnosis: chicken pox. Patient remained on droplet isolation precautions and received Acyclovir and Moxifloxacin. Hospital Principal Diagnosis: Varicella vaccine induced chickenpox. Discharge: Patient lesions crusted and the lesions are no longer contagious, returned to military.  10/23/2008 MR received for DOS 8/30-9/2/2008 with D/C DX:  Varicella Vaccine Induced Chicken Pox.  Pt presented with vesicular/pustular rash all over x 2 days.  Pt has inguinal and submandibular lymphadenopathy. Worsening productive cough with yellow/green sputum x 3 weeks. Pt placed on contact and airborn isolation and tx with Acyclovir and Moxifloxin. D/C when lesions crusted over.
A severe allergic reaction; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (A severe allergic reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (A severe allergic reaction). At the time of the report, HYPERSENSITIVITY (A severe allergic reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Pt vaccinated with DTP/MMR/OPV experienced "shaking" episode & was hot; Rectal Temp 104; Seen by MD exam was normal & described episode as a questionable febrile seizure.
After 2nd vaccination - patient was having trouble breathing whenever she worked out in the yard doing minor task such as raking leaves/gumballs.  She had 3 or more episodes of feeling light-headed and stopping activity and walking into living room and sitting.  Was able to catch breath and didn't want to go to hospital in any of these cases.  However on March 8 at 3pm, she felt light-headed but on her way back to her living room, her breathing was disrupted.  Her breaths were cut short and she was not receiving much air into her lungs.  The breaths were shorter and shorter until she wasn't receiving hardly any air into her lungs. Her face turned blue.  She passed out.  She had CPR administered about 30 seconds after passing out.  Ambulance arrived about 1 minute after passing out.  EMT crew worked on her for 18 minutes and was ready to contact coroner when they got a heartbeat.  She was taken to hospital on March 8.  She was transferred to another hospital later than night.  She was sent home for hospice (still unconscious) on March 16 or 17. She passed morning of March 19.  Death certificate states cause of death was lack of oxygen to the brain, but no determination was made to what caused her breathing problems, which caused the lack of oxygen to her brain.  EMT crew said her symptoms were very similar to blood clot in lungs. Hospital ruled out a blood clot.  They also downloaded data from the pacemaker and ruled out A-Fib as the cause.  Pacemaker data had indicated a mild event around 3pm on March 8 and sent a shock to her heart but nothing unusual.  I believe the hospital also ruled out another cause or two, but never did determine the cause.
This spontaneous report as received from a physician via company representative refers to a male patient of unknown age. There were no concomitant medications, concurrent conditions and medical history reported. On an unknown date, the patient was vaccinated with his first dose of GARDASIL (route of administration, dose, lot number and expiration date were not reported) or GARDASIL 9 (route of administration, dose, lot number and expiration date were not reported). The physician unknown which vaccine was administered. On an unknown date, the patient developed hives and a rash around the periphery of the injection site. The patient sought unspecified medical attention. The outcome of the events was unknown. The relatedness between the events and suspect therapies was not reported. Additional information has been requested.
Info regarding Prevnar injection was received from a healthcare professional regarding a 12 month old male pt who experienced puffy eyes. A 12 months of age, the pt received the fifth dose on 6/29/05. Indication for Prevnar was immunization. Product was administered on 6/29/05. Dose regimen was 1 dose, IM. Additional suspect medication included Pentacel (diphtheria vaccine/haemophilus influenzae b/acellular pertussis vaccine/poliomyelitis vaccine inactivated/tetanus vaccine). Concomitant medications were not reported. Event Details: The pt developed puffy eyes (eye swelling) on either 6/30/05 or 7/1/05. Around this same time, the child had eaten Bing cherries and popsicle which he had not eaten before. The child also had sunscreen applied; the physician thought that the sunscreen was the possible cause of the puffy eyes; food allergy testing was not done. The eyes cleared by 7/3/05. No more info was available at the time of this report.
Adverse Event: PT reported that she had previously experienced tachycardia and chest pain after her first dose of the Pfizer vaccine. PT was provided vaccine sitting on cot in curtained area.  After this dose was administered, PT c/o nausea and stomach pain. Aid was called at 1425, arrived at 1430 and assumed care of PT. Treatment: PT was provided juice, EMTs assessed PT. Outcome: PT appeared to have returned to baseline, was able to sit up without change in condition.  PT reported lingering pain at injection site. Was medically cleared by EMS and left in private vehicle in wheelchair accompanied by friend.  HCP Responding: RNS, EMTS
Initial unsolicited report received from a pharmacist (Director of Pharmacy) on 12-OCT-2016. This case is linked with 2016SA189772, 2016SA189781, 2016SA189791, 2016SA189792, 2016SA189793, 2016SA189794, 2016SA189795, 2016SA189796, 2016SA189797, 2016SA189798, 2016SA189799, 2016SA189800, 2016SA189801, 2016SA189802, 2016SA189803, 2016SA189804, 2016SA189805, 2016SA189806, 2016SA189807, 2016SA189808, 2016SA189809, 2016SA189810, 2016SA189811, 2016SA189812, 2016SA189813, 2016SA189814, 2016SA189815, 2016SA189816, 2016SA189817, 2016SA189818, 2016SA189819, 2016SA189820, 2016SA189821, 2016SA189822, 2016SA189823, 2016SA189824, 2016SA189825, 2016SA189826, 2016SA189827, 2016SA189828, 2016SA189829, 2016SA189830, 2016SA189831, 2016SA189832, 2016SA189833, 2016SA189834, 2016SA189835, 2016SA189836, 2016SA189837, 2016SA189839, 2016SA189840, 2016SA189841, 2016SA189842, 2016SA189843, 2016SA189844, 2016SA189845, 2016SA189846, 2016SA189847, 2016SA189848. This case involves a patient (age and gender not reported) who was vaccinated with a dose of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED (FLUZONE) batch number: UI669AA, expiration date: 30-JUN-2017, intramuscularly, on 04-OCT-2016. Patient's Illness at time of vaccination and Pre-existing physician diagnosed allergies, birth defects, medical conditions was reported as unknown. Concomitant medications were not reported. On an unspecified date (over the past month), following the vaccination, the patient experienced local reaction: hard, itchy lump. It was reported that the patient required emergency room/doctor visit. Lab data and corrective treatment were not reported. The outcome of the events was reported as unknown. List of documents held by sender: none.
This was my Moderna Booster shot. 10 days after my I recieved my booster short I had these 3 big bumps on my right elbow that looked like bug bites and itched at 3:05 PM on 11/30/21. By the time I got home after work I was changing at 5:10 PM and saw that I had a rash on my right hip bone, on my stomach that looked like a big welt, & all over my chest taking benadryl that afternoon when I was home into the next morning on 12/01/21. My symptoms only got worse. I had rashes on my back, buttox, all down my legs, top of my feet, my chest, stomach, neck, face and back of head. I went to ER & got meds. 12/02/21- Rashes appear better and covering less of my body, but are still welts appearing itching in different areas.
Vaccine was administered 8/24/2023. Patient reports muscle pain in the arm of the vaccine injection on 8/28/2023. Patient also complains of redness and feeling warm sensation in that arm. Redness is around the vaccine injection site. Patient will go to urgent care to be evaluated for potential soft and tissue infection.
Fever for two days after receiving the immunization.  Headaches, malaise, body aches, and fatigue.
This spontaneous report as received from a physician and from a support services director refers to a patient of unknown age and gender. No information regarding the patient's medical history or concurrent conditions was provided. On 25-MAY-2016, the patient was vaccinated with an improperly stored ROTATEQ 2 ml oral injection (lot# L008997, expiry fate 04-DEC-2020; dose and route of administration were not reported). There were no concomitant therapies reported. The dose of the vaccine was exposed to two separate temperature excursion (dates unspecified): one lasting for 712 hours, with the lowest recorded temperature of 34 degrees Fahrenheit and the second one lasting for 168 hours, with the lowest recorded temperature of 32 degrees Fahrenheit. The vaccine was stored in a refrigerator. No adverse effects were reported. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
Vaccine dates: 4/22/2019 and 7/3/2019 / shingles last week/suspected vaccination failure; shingles las week; This case was reported by a physician via sales rep and described the occurrence of vaccination failure in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   On 22nd April 2019, the patient received the 1st dose of Shingrix. On 3rd July 2019, the patient received the 2nd dose of Shingrix. In August 2020, between 1 and 2 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group of the patient was not reported, but selected as an adult as per vaccine indication. Last week from the date of reporting, the patient experienced shingles. This was considered as a suspected vaccination failure since the details regarding laboratory test confirming singles were not provided.
One of his friend was paralyzed after taking moderna vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PARALYSIS (One of his friend was paralyzed after taking moderna vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PARALYSIS (One of his friend was paralyzed after taking moderna vaccine) (seriousness criterion medically significant). At the time of the report, PARALYSIS (One of his friend was paralyzed after taking moderna vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication of the patient was not reported.  No treatment information was provided by the reporter.  Company comment: Based on the currently available information, this case is invalid. Due to the paucity of information, a causality assessment appears not possible.; Sender's Comments: Based on the currently available information, this case is invalid. Due to the paucity of information, a causality assessment appears not possible.
Felt cold; Sinuses were messed up; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (Felt cold), SINUS DISORDER (Sinuses were messed up) and PAIN (Body aches) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, the patient experienced NASOPHARYNGITIS (Felt cold), SINUS DISORDER (Sinuses were messed up) and PAIN (Body aches). At the time of the report, NASOPHARYNGITIS (Felt cold), SINUS DISORDER (Sinuses were messed up) and PAIN (Body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  Treatment medication was not provided by the reporter.
Severe Headache 4/8-ongoing Sore throat 4/9-ongoing Fever 100*+  4/9-4/11  Chills 4/9- ongoing Nausea 4/8- ongoing Vomiting 4/8-4/11 Diarrhea 4/8- ongoing  Pain in arm 4/8- ongoing Unable to use left arm due to muscle issues  4/8-4/11 Debilitating Fatigue 4/8-ongoing